Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company based in Tel Aviv, is advancing its innovative therapies for fibro-inflammatory diseases, particularly primary sclerosing cholangitis (PSC). The company is set to present clinical data on its lead candidate, nebokitug (CM-101), at several prominent scientific conferences in 2025, including Digestive Disease Week (DDW25), the European Association for the Study of the Liver (EASL) Congress, and the British Society of Gastroenterology (BSG).

Chemomab’s nebokitug is a first-in-class monoclonal antibody that targets the soluble protein CCL24, which plays a crucial role in fibrosis and inflammation processes associated with PSC. The presentations aim to highlight findings from the Phase 2 SPRING trial, demonstrating that CM-101 was both safe and well-tolerated, with significant improvement in biomarkers linked to inflammation and disease progression.

Dr. Paul Pockros will deliver an oral presentation at DDW25 on May 4, 2025, emphasizing the promising results of the SPRING Study. Following that, CEO Dr. Adi Mor will lead two poster presentations at EASL 2025 on May 8 and 9, focusing on pharmacokinetics, pharmacodynamics, and proteomic profiling in PSC patients. Dr. Douglas Thorburn will also present findings at BSG Live from June 23-26, 2025.

Chemomab has previously reported positive outcomes from several clinical trials for nebokitug and is preparing to initiate a pivotal Phase 3 clinical trial for PSC. The drug has received Orphan Drug designations from the FDA and EMA, as well as FDA Fast Track designation, paving the way for a streamlined approval process. The company’s commitment to addressing severe fibro-inflammatory diseases aligns with its goal to provide critical therapeutic options for underserved patient populations. For more information, visit chemomab.com.

Chemomab Therapeutics (Nasdaq: CMMB), specializing in innovations for fibro-inflammatory diseases, is poised for a pivotal moment as it prepares to present new data on its monoclonal antibody nebokitug (CM-101) at major scientific gatherings in the coming weeks. With presentations scheduled at Digestive Disease Week 2025, EASL 2025, and BSG LIVE'25, investors should closely monitor these events, as the data shared could significantly influence the company's stock performance.

For investors, the results of the Phase 2 SPRING study, particularly focusing on primary sclerosing cholangitis (PSC), are expected to bolster Chemomab’s valuation if they are positive. Notably, nebokitug has already garnered Orphan Drug and Fast Track designations from both FDA and EMA, highlighting its potential as a differentiated therapy in an underserved market. The preliminary outcomes indicated improvements in inflammation and fibrosis biomarkers, positioning CM-101 as a promising candidate for further clinical exploration.

Investors should note the structured plan for a Phase 3 trial, as Chemomab's pathway to approval appears efficient, potentially leading to a quicker commercialization timeline. This could be especially appealing to long-term investors looking for opportunities in biotech.

Nevertheless, it is critical for investors to be aware of market volatility surrounding clinical data releases. Historical trends suggest that successful outcomes can drive stock prices upward sharply, whereas disappointing results could lead to significant declines. Therefore, maintaining a diversified portfolio can mitigate risk.

In summary, Chemomab presents a compelling investment opportunity, especially with potentially favorable data on the horizon. However, investors should remain vigilant about the risks associated with clinical data announcements and market reactions. Monitoring the upcoming conferences will be crucial for assessing the stock's trajectory moving forward.